CRAMS stocks doing well

JUBILANT Organosys won a long-term CRAMS contract worth $51 million from from a leading US life sciences company. http://www.capitalmarket.com/if.asp?L=hotpursuit&M=cmedit/story2-0.asp?sno=419544
Jubilant the latest CRAMS deal with a US firm is a take or pay contract with agreed quantities. Further, the company is in discussions to increase the contract size to more than 2.5 times, it said. R. Sankaraiah, Jubilant's executive director, finance, was quoted by the media as saying that with the new deal, the company's CRAMS order book has crossed $1 billion. Jubilant continues to see strong traction in CRAMS business and expects to sign few more contracts during the year which will further drive the momentum in revenue and profitability, Jubilant said in a statement.

Even GLENMARK which is another CRAMS stock looks very good. We hold both JUBILANT and GLENMARK in FAB-15 where targets of Rs 450 and Rs 350 respectively may happen very soon.

CRAMS : India, A Low-Cost Hub http://iupindia.in/810/AN_CRAMS_India_50.html
http://hindi.economictimes.indiatimes.com/articleshow/6319013.cms ए के प्रभाकर, स्वतंत्र तकनीकी विश्लेषक